ArticleScientific reports2026
Ginsenoside Rg1 ameliorates lipopolysaccharide-induced depressive-like behaviors in mice by attenuating neuroinflammation and neuronal damage.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Ginsenoside Rg1 (Rg1), a major active component of ginseng, exerts antidepressant-like effects, but the mechanisms underlying its anti-inflammatory activity and association with hippocampal neuronal remain unclear. A depression model was established in ICR mice via lipopolysaccharide (LPS) injection to investigate the effects of Rg1 on neuroinflammation and neuronal injury, as well as its antidepressant mechanism. Cognitive dysfunctions were evaluated via forced swim test (FST), sucrose preference test (SPT) and elevated plus maze (EPM). The effects of LPS-induced neuronal damage and Rg1 on anti-inflammatory pathways were subsequently evaluated through biochemical assays, and histological analysis, including Hematoxylin and Eosin staining, Nissl staining, Immunohistochemistry, ELISA and transmission electron microscopy (TEM). After confirming Rg1's antidepressant activity, its possible mechanisms were analyzed through Proteomic. Finally, Western blot was used to detect the key targets for predictive mechanisms. Results showed Rg1 significantly ameliorated LPS-induced depressive-like behaviors, reduced serum pro-inflammatory cytokines, attenuated neuronal loss, and increased hippocampal NeuN-positive cell density. The p-MST1/MST1 and p-YAP/YAP ratios were elevated in the model group but reversed by Rg1 and fluoxetine treatment. This study indicated Rg1 exerts antidepressant effect in mice, possibly by inhibiting hyperphosphorylation of key Hippo-YAP signaling pathway proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.